NCI declares state of crisis in trials

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 19 No 5
Volume 19
Issue 5

An NCI report concluded that our clinical trial system is nearing a “state of crisis.” This seems like a case of new report, same conclusion.

An NCI report concluded that our clinical trial system is nearing a "state of crisis." This seems like a case of new report, same conclusion. "A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program," identified reasons for our system's lack of production including the time it takes to organize and launch a trial: More than two years of slugging through a Kafkaesque maze of bureaucracy and, if the trial finishes at all, the compound or therapy has a good chance of being out of date. Randomized controlled trials are still the gold standard for cancer agents to move from bench to bedside. We need to make it a national priority to streamline this overwrought process.

Related Videos
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Related Content